Replies to post #494173 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Prof. Stephen Macfarlane is listed as the first author

https://pmc.ncbi.nlm.nih.gov/articles/PMC12184016/

Good luck and GOD bless,

[Investor2014]

It was actually Stephen MacFarlane who was the lead author both on the P2a and the P2b/3 AD trial papers, but - Yes and keep in mind that drugs with brilliant peer reviewed papers written by highly respect folks does not always equate to drug approval.

I have several times recounted why at present I assign a 25% chance of approval for A2-73 in AD from current trials data, which doesn't of course excluded approval - it is just IMO less likely that many here believe.

If/when the EMA clock starts ticking again, as I have also said many times, my odds of approval goes up!

I very much hope the clock WILL start ticking soon!
.

[sab63090]

Guzzi62

Thanks you gave reason for my post to Investor!

[LakeshoreLeo1953]

I have been told from one in the know that the first name in a
peer reviewed medical journal is the lead author and basically wrote it,
the rest of the persons are just confirming what is written is correct
from their part of the trial as you also hinted.

Many here would benefit from your "in the know" friend's opinion.